GAIN THERAPEUTICS, INC Research and Development Expense
GAIN THERAPEUTICS, INC (GANX) reported Research and Development Expense of $2.14 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-11
- GAIN THERAPEUTICS, INC research and development expense for the quarter ending 2026-06-30 was $2.14M, a 22.50% decline year-over-year.
- GAIN THERAPEUTICS, INC research and development expense for the quarter ending 2026-03-31 was $2.76M, a 22.43% increase year-over-year.
- GAIN THERAPEUTICS, INC research and development expense for the quarter ending 2025-12-31 was $2.35M, a 91.65% increase year-over-year.
- GAIN THERAPEUTICS, INC research and development expense for the quarter ending 2025-09-30 was $2.85M, a 8.69% increase year-over-year.
- GAIN THERAPEUTICS, INC research and development expense for fiscal 2025 was $10.21M, a 5.36% decline from fiscal 2024.
- GAIN THERAPEUTICS, INC research and development expense for fiscal 2024 was $10.79M, a 6.33% decline from fiscal 2023.
- GAIN THERAPEUTICS, INC research and development expense for fiscal 2023 was $11.52M, a 37.52% increase from fiscal 2022.
- GAIN THERAPEUTICS, INC research and development expense for fiscal 2022 was $8.38M, a 16.93% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.14M 10-Q · filed 2026-08-11 | $4.90M 10-Q · filed 2026-08-11 | $7.25M derived: sum of 3 quarters · filed 2026-08-11 | $10.10M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $2.76M 10-Q · filed 2026-05-11 | $5.11M derived: sum of 2 quarters · filed 2026-05-11 | $7.96M derived: sum of 3 quarters · filed 2026-05-11 | $10.72M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $2.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $5.20M derived: sum of 2 quarters · filed 2026-03-26 | $7.96M derived: sum of 3 quarters · filed 2026-08-11 | $10.21M 10-K · filed 2026-03-26 |
| 2025-09-30 | $2.85M 10-Q · filed 2025-11-12 | $5.61M derived: sum of 2 quarters · filed 2026-08-11 | $7.87M 10-Q · filed 2025-11-12 | $9.09M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $2.76M 10-Q · filed 2026-08-11 | $5.02M 10-Q · filed 2026-08-11 | $6.24M derived: sum of 3 quarters · filed 2026-08-11 | $8.86M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $2.26M 10-Q · filed 2026-05-11 | $3.48M derived: sum of 2 quarters · filed 2026-05-11 | $6.10M derived: sum of 3 quarters · filed 2026-05-11 | $10.54M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $1.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $3.85M derived: sum of 2 quarters · filed 2026-03-26 | $8.28M derived: sum of 3 quarters · filed 2026-03-26 | $10.79M 10-K · filed 2026-03-26 |
| 2024-09-30 | $2.62M 10-Q · filed 2025-11-12 | $7.06M derived: sum of 2 quarters · filed 2025-11-12 | $9.57M 10-Q · filed 2025-11-12 | $11.94M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $4.44M 10-Q · filed 2025-08-12 | $6.94M 10-Q · filed 2025-08-12 | $9.32M derived: sum of 3 quarters · filed 2025-08-12 | $11.69M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $2.51M 10-Q · filed 2025-05-14 | $4.88M derived: sum of 2 quarters · filed 2025-05-14 | $7.25M derived: sum of 3 quarters · filed 2025-05-14 | $11.24M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $2.37M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $4.74M derived: sum of 2 quarters · filed 2025-03-27 | $8.73M derived: sum of 3 quarters · filed 2025-03-27 | $11.52M 10-K · filed 2025-03-27 |
| 2023-09-30 | $2.37M 10-Q · filed 2024-11-14 | $6.36M derived: sum of 2 quarters · filed 2024-11-14 | $9.15M 10-Q · filed 2024-11-14 | $11.42M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $3.99M 10-Q · filed 2024-08-08 | $6.78M 10-Q · filed 2024-08-08 | $9.05M derived: sum of 3 quarters · filed 2024-08-08 | $11.02M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $2.79M 10-Q · filed 2024-05-14 | $5.07M derived: sum of 2 quarters · filed 2024-05-14 | $7.03M derived: sum of 3 quarters · filed 2024-05-14 | $9.61M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $2.27M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $4.24M derived: sum of 2 quarters · filed 2024-03-26 | $6.82M derived: sum of 3 quarters · filed 2024-03-26 | $8.38M 10-K · filed 2024-03-26 |
| 2022-09-30 | $1.96M 10-Q · filed 2023-11-14 | $4.55M derived: sum of 2 quarters · filed 2023-11-14 | $6.10M 10-Q · filed 2023-11-14 | $7.58M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $2.58M 10-Q · filed 2023-08-10 | $4.14M 10-Q · filed 2023-08-10 | $5.61M derived: sum of 3 quarters · filed 2023-08-10 | $8.09M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $1.56M 10-Q · filed 2023-05-12 | $3.03M derived: sum of 2 quarters · filed 2023-05-12 | $5.51M derived: sum of 3 quarters · filed 2023-05-12 | $7.30M derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | $1.47M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $3.95M derived: sum of 2 quarters · filed 2023-03-23 | $5.74M derived: sum of 3 quarters · filed 2023-03-23 | $7.16M 10-K · filed 2023-03-23 |
| 2021-09-30 | $2.48M 10-Q · filed 2022-11-10 | $4.27M derived: sum of 2 quarters · filed 2022-11-10 | $5.69M 10-Q · filed 2022-11-10 | $6.67M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $1.79M 10-Q · filed 2022-08-08 | $3.22M 10-Q · filed 2022-08-08 | $4.19M derived: sum of 3 quarters · filed 2022-08-08 | $4.62M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $1.42M 10-Q · filed 2022-05-16 | $2.40M derived: sum of 2 quarters · filed 2022-05-16 | $2.82M derived: sum of 3 quarters · filed 2022-05-16 | $3.26M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $975.61K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-25 | $1.40M derived: sum of 2 quarters · filed 2022-03-25 | $1.84M derived: sum of 3 quarters · filed 2022-03-25 | $2.26M 10-K · filed 2022-03-25 |
| 2020-09-30 | $427.46K 10-Q · filed 2021-11-12 | $866.33K derived: sum of 2 quarters · filed 2021-11-12 | $1.28M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $438.87K 10-Q · filed 2021-08-12 | $856.13K 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $417.26K 10-Q · filed 2021-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B |